20554-95-4
Chemical Structure
Faradiol
- CAS No.: 20554-95-4
- Formula:C30H50O2
- Molecular Weight:442.72
IUPAC Name: (3S,4aR,6aR,6bR,8S,8aS,12S,12aR,12bR,14aR,14bR)-4,4,6a,6b,8a,11,12,14b-octamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,12,12a,12b,13,14,14a,14b-icosahydropicene-3,8-diol
InChIKey: BNHIQKVOPNHQKO-IMLFCHQCSA-N
SMILES: CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC[C@]4([H])[C@@]5([H])[C@H](C)C(C)=CC[C@@](C)5[C@@H](O)C[C@](C)4[C@@](C)3CC[C@@]12[H]
Biological Activity: Faradiol is a STAT3 inhibitor. Faradiol exerts anti-inflammatory activity by reducing STAT3 phosphorylation in a concentration-dependent manner and inhibiting LPS-induced IL-6 release from human monocytes, while also exhibiting cytotoxicity against leukemia and non-small cell lung cancer cells. Faradiol can be used in research on leukemia, edema, cancer, non-small cell lung cancer, Phorbol 12-myristate 13-acetate (TPA) (HY-18739)-induced inflammation, and skin tumors[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Faradiol | Faradiol is a STAT3 inhibitor. Faradiol exerts anti-inflammatory activity by reducing STAT3 phosphorylation in a concentration-dependent manner and inhibiting LPS-induced IL-6 release from human monocytes, while also exhibiting cytotoxicity against leukemia and non-small cell lung cancer cells. Faradiol can be used in research on leukemia, edema, cancer, non-small cell lung cancer, Phorbol 12-myristate 13-acetate (TPA) (HY-18739)-induced inflammation, and skin tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Golubova D, et al. Biosynthesis and bioactivity of anti-inflammatory triterpenoids in Calendula officinalis. Nature communications. 2025 Jul 28;16(1):6941.
- [2]. Fronza M, et al. Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts. Journal of ethnopharmacology. 2009 Dec 10;126(3):463-7.
- [3]. Vela Gurovic MS, et al. Cytotoxic effects induced by combination of heliantriol B2 and dequalinium against human leukemic cell lines. Phytotherapy Research. 2011 Apr;25(4):603-10.
- [4]. Zitterl-Eglseer K, et al. Anti-oedematous activities of the main triterpendiol esters of marigold (Calendula officinalis L.). Journal of ethnopharmacology. 1997 Jul;57(2):139-44.
- [5]. Ukiya M, et al. Constituents of Compositae plants III. Anti-tumor promoting effects and cytotoxic activity against human cancer cell lines of triterpene diols and triols from edible chrysanthemum flowers. Cancer letters. 2002 Mar 08;177(1):7-12.
- [6]. Dzubak P, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Natural product reports. 2006 Jun 1;23(3):394-411.
- [7]. Ukiya M, et al. Constituents of compositae plants. 2. Triterpene diols, triols, and their 3-o-fatty acid esters from edible chrysanthemum flower extract and their anti-inflammatory effects. Journal of agricultural and food chemistry. 2001 Jul;49(7):3187-97.
- [8]. Yasukawa K, et al. Inhibitory effect of heliantriol C; a component of edible Chrysanthemum, on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Phytomedicine : international journal of phytotherapy and phytopharmacology. 1998 May;5(3):215-8. [Content Brief]
